00
000623.SHE Jilin Aodong Pharmaceutical Group Co Ltd
- Market cap
- CNY 20.1B
- P/E
- 6.6x
- P/B
- 0.61x
- ROE
- 11.6%
- Dividend yield
- 3.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000623.SHE undervalued?
Graham number000623.SHE trades 57.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jilin Aodong Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Jilin Aodong Pharmaceutical Group Co Ltd yet.
Jilin Aodong Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jilin Aodong Pharmaceutical Group Co Ltd
Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China. It provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in the highway construction and toll collection businesses; animal husbandry activities; manufacture of spec…
Full company profileJilin Aodong Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jilin Aodong Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.74B | 2.98B | 3.32B | 3.09B | 2.25B | 2.30B | 2.87B | 3.45B | 2.61B | 2.34B | 2.06B |
| Gross Profit | 1.91B | 2.09B | 2.38B | 2.12B | 1.32B | 1.19B | 1.45B | 1.68B | 1.01B | 1.13B | 967M |
| Operating Income | 1.63B | 1.93B | 978M | 1.48B | 1.72B | 1.76B | 1.13B | 1.38B | 1.50B | -62.9M | 80.0M |
| EBITDA | 503M | 482M | 462M | 368M | 130M | 200M | 326M | 340M | 45.5M | 2.69B | 3.82B |
| Net Income | 1.67B | 1.86B | 935M | 1.40B | 1.71B | 1.78B | 1.78B | 1.46B | 1.55B | 2.40B | 3.81B |
| EPS | 1.45 | 1.60 | 0.80 | 1.10 | 1.34 | 1.41 | 1.37 | 1.23 | 1.32 | 2.00 | 3.19 |
| Balance Sheet | |||||||||||
| Total Assets | 20.3B | 21.8B | 24.7B | 25.8B | 27.4B | 29.1B | 31.2B | 32.3B | 33.0B | 34.4B | 36.4B |
| Total Liabilities | 1.47B | 1.32B | 3.41B | 3.36B | 3.88B | 4.03B | 4.84B | 4.77B | 3.72B | 3.53B | 3.59B |
| Shareholders' Equity | 18.6B | 20.3B | 21.0B | 22.2B | 23.4B | 24.9B | 26.0B | 27.2B | 29.0B | 30.7B | 32.8B |
| Cash & Short-term Investments | 1.79B | 1.47B | 2.66B | 3.10B | 3.80B | 3.93B | 3.08B | 3.38B | 2.68B | 1.16B | 1.38B |
| Total Debt | 134M | 12.5M | 2.01B | 2.09B | 2.52B | 2.59B | 2.97B | 700M | 2.27B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 334M | 256M | 348M | 379M | 390M | 325M | 424M | 68.1M | 59.5M | 272M | - |
| Capital Expenditure | 158M | 83.9M | 245M | 222M | 227M | 313M | 271M | 420M | 274M | 128M | 85.0M |
| Free Cash Flow | 176M | 173M | 102M | 157M | 163M | 11.5M | 153M | -351M | -214M | 144M | 178M |
| Ratios | |||||||||||
| ROE | 8.9% | 9.2% | 4.4% | 6.3% | 7.3% | 7.2% | 6.8% | 5.4% | 5.3% | 7.8% | 11.6% |
| ROA | 8.2% | 8.5% | 3.8% | 5.4% | 6.2% | 6.1% | 5.7% | 4.5% | 4.7% | 7.0% | 10.5% |
| Net Profit Margin | 60.9% | 62.6% | 28.1% | 45.4% | 75.9% | 77.3% | 62.1% | 42.3% | 59.4% | 102.6% | 185.2% |
| Debt to Equity | 0.01x | 0.00x | 0.10x | 0.09x | 0.11x | 0.10x | 0.11x | 0.03x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jilin Aodong Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 3.22%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 27.1%
- Ex-dividend date
- Oct 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 649M | 0.54 | 27.1% |
| 2024 | CNY 1.06B | 0.90 | 68.3% |
| 2023 | CNY 338M | 0.28 | 23.2% |
| 2022 | CNY 341M | 0.26 | 19.2% |
| 2021 | CNY 256M | 0.20 | 14.4% |
| 2020 | CNY 232M | 0.18 | 13.6% |
| 2019 | CNY 241M | 0.19 | 17.2% |
| 2018 | CNY 351M | 0.30 | 37.6% |
| 2017 | CNY 271M | 0.23 | 14.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jun 19, 2017.
Who owns Jilin Aodong Pharmaceutical Group Co Ltd
- Insiders 33.37%
- Institutions 6.83%
- Public & others 59.81%
- Shares outstanding 1.20B
- Free float 807M
Jilin Aodong Pharmaceutical Group Co Ltd company profile
- Company name
- Jilin Aodong Pharmaceutical Group Co Ltd
- Ticker
- 000623.SHE
- ISIN
- CNE000000719
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 8, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,461
- Fiscal year end
- December
- Address
- No. 2158, Aodong Street, Dunhua, China, 133700
- Phone
- 86 43 3623 8973
- Website
- jlaod.com
About Jilin Aodong Pharmaceutical Group Co Ltd
Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China. It provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; production and sale of packaging materials; and information consulting and advertising design and production activities. In addition, the company offers pharmaceutical excipients and packaging materials; produces and sells enzyme stock solutions; ginseng and antler products; sells health care products; and processes edible agricultural products, etc. Jilin Aodong Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Dunhua, China.
Jilin Aodong Pharmaceutical Group Co Ltd management
7- Ms. Shuqin GuoVice Chairman & GM · born 1963
- Ms. Shuyuan Zhang CPACFO, Financial Director, Deputy GM & Director · born 1972
- Mr. Kai YangDeputy GM & Director · born 1977
- Mr. Zhen Yu WangDeputy GM, Secretary of the Board & Director · born 1981
- Mr. Xiaolin LinDeputy General Manager · born 1978
- Mr. Chao WangDeputy General Manager · born 1975
- Qiang LiAccounting Supervisor